Short Interest in Health Catalyst, Inc. (NASDAQ:HCAT) Expands By 18.1%

Health Catalyst, Inc. (NASDAQ:HCAT) saw a large increase in short interest in February. As of February 27th, there was short interest totaling 6,750,287 shares, an increase of 18.1% from the February 12th total of 5,716,947 shares. Based on an average trading volume of 1,060,809 shares, the short-interest ratio is currently 6.4 days. Currently, 9.8% of the company’s stock are sold short. Currently, 9.8% of the company’s stock are sold short. Based on an average trading volume of 1,060,809 shares, the short-interest ratio is currently 6.4 days.

Health Catalyst Stock Down 2.1%

Health Catalyst stock traded down $0.03 during trading hours on Wednesday, reaching $1.15. The stock had a trading volume of 998,950 shares, compared to its average volume of 869,684. The company has a market cap of $84.26 million, a price-to-earnings ratio of -0.45 and a beta of 1.77. The business’s 50 day moving average price is $2.01 and its 200-day moving average price is $2.52. Health Catalyst has a 52 week low of $1.04 and a 52 week high of $5.06. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.89 and a quick ratio of 1.89.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Thursday, March 12th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). The firm had revenue of $74.68 million during the quarter, compared to the consensus estimate of $73.99 million. Health Catalyst had a negative net margin of 57.20% and a negative return on equity of 4.30%. Sell-side analysts anticipate that Health Catalyst will post -0.33 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on HCAT. Stifel Nicolaus reduced their price target on shares of Health Catalyst from $3.75 to $2.00 and set a “hold” rating for the company in a report on Friday, March 13th. Cantor Fitzgerald dropped their price objective on shares of Health Catalyst from $4.00 to $3.00 and set a “neutral” rating on the stock in a research note on Friday, March 13th. Citigroup cut their price objective on shares of Health Catalyst from $2.75 to $1.75 and set a “neutral” rating on the stock in a report on Friday, March 13th. Raymond James Financial set a $3.00 price objective on shares of Health Catalyst in a research note on Friday, March 13th. Finally, Canaccord Genuity Group lowered their target price on Health Catalyst from $5.00 to $2.00 and set a “buy” rating for the company in a report on Friday, March 13th. Four research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Health Catalyst currently has a consensus rating of “Hold” and a consensus target price of $2.80.

Hedge Funds Weigh In On Health Catalyst

Institutional investors and hedge funds have recently bought and sold shares of the company. nVerses Capital LLC purchased a new stake in shares of Health Catalyst during the 4th quarter valued at $25,000. Pilgrim Partners Asia Pte Ltd purchased a new position in Health Catalyst during the 3rd quarter worth $39,000. Cresset Asset Management LLC purchased a new position in Health Catalyst during the 2nd quarter worth $39,000. FNY Investment Advisers LLC acquired a new position in Health Catalyst during the 3rd quarter valued at about $45,000. Finally, Focus Partners Wealth acquired a new position in Health Catalyst during the 1st quarter valued at about $46,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.